Vanquish Oncology, Inc.
Vanquish Oncology Inc. is a drug development company focused on targeting molecular defects in cancer cells to create personalized therapeutics for unmet or underserved cancer markets. They are developing procaspase 3 activators as orally delivered therapies, with a focus on inducing apoptosis in cancer cells, including those in the brain. Their pipeline includes first and second generation procaspase activators and combination products, leveraging a proprietary P3A program. The company was founded by Professor Paul J. Hergenrother and others, and is based on technology licensed from the University of Illinois.
Industries
Nr. of Employees
small (1-50)
Vanquish Oncology, Inc.
2001 S. First St. Suite 201 Champaign, IL 61820
Patents
Products
Procaspase-3 activator (clinical candidate)
A development-stage small-molecule clinical candidate that directly activates procaspase-3 to induce apoptosis selectively in cancer cells; advanced through preclinical efficacy, DMPK and toxicity testing and progressed to Phase I clinical evaluation.
Procaspase-3 activator (clinical candidate)
A development-stage small-molecule clinical candidate that directly activates procaspase-3 to induce apoptosis selectively in cancer cells; advanced through preclinical efficacy, DMPK and toxicity testing and progressed to Phase I clinical evaluation.
Services
Outsourced execution and coordination of in vitro and in vivo efficacy testing, DMPK and toxicology studies, and CMC activities required for IND submissions.
Sponsorship and coordination of first-in-human Phase I clinical trials, including site collaboration with academic cancer centers.
Outsourced execution and coordination of in vitro and in vivo efficacy testing, DMPK and toxicology studies, and CMC activities required for IND submissions.
Sponsorship and coordination of first-in-human Phase I clinical trials, including site collaboration with academic cancer centers.
Expertise Areas
- Targeted small-molecule oncology therapeutics
- Preclinical development and translational research
- IND-enabling studies and regulatory preparation
- Phase I clinical trial execution (dose-escalation)
Key Technologies
- Procaspase-3 activation (small-molecule mechanism)
- Cell-based apoptosis assays
- Rodent xenograft and metastasis models
- Spontaneous canine tumor models
News & Updates
A drug known as PAC-1, which spurs cancer cells to self-destruct while sparing healthy cells, is moving towards human clinical trials following promising results in cell culture, mouse models, and pet dogs with spontaneously occurring lymphomas and osteosarcomas.
The Phase 1 clinical trial of PAC-1, a procaspase 3 activator, is beginning at the University of Illinois Cancer Center in Chicago. The trial is a dose-escalation study for advanced malignancies.
A drug known as PAC-1, which spurs cancer cells to self-destruct while sparing healthy cells, is moving towards human clinical trials following promising results in cell culture, mouse models, and pet dogs with spontaneously occurring lymphomas and osteosarcomas.
The Phase 1 clinical trial of PAC-1, a procaspase 3 activator, is beginning at the University of Illinois Cancer Center in Chicago. The trial is a dose-escalation study for advanced malignancies.